MDS

The European Commission has approved Rytelo treatment in transfusion-dependent anemia due to very low–, low– or intermediate-risk myelodysplastic syndrome.

As a cancer survivor, I talk about where to look for the light when in utter darkness.

As a cancer survivor, I describe battling both cancer and infections and the toll it takes on my body.

I have been frustrated lately by my increasing slowness following an blood cancer diagnosis, which has become noticeable to others.

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations like AML, MDS and breast cancer.

The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with myelodysplastic syndrome.

After a long and difficult journey, I finally published the book I set out to write as my legacy, overcoming cancer and the challenges of deafness.

The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome prior to alloHSCT.

As a survivor of MDS, I’ve learned to make the best of every day and to be thankful for life. Sometimes this means avoiding others who are less grateful.

The Venclexta-based regimen improved complete response rates in patients with acute myeloid leukemia and myelodysplastic syndromes.

Results from the study also showed the potential association between smoking, disease progression and survival in patients with myelodysplastic syndromes.

The novel treatment is being evaluated for patients with previously treated transfusion-dependent lower-risk myelodysplastic syndrome.

Patients with relapsed or refractory MDS may experience improved overall survival with DLI, depending on certain prognostic factors.

Researchers have found an overall survival benefit and manageable safety profile with Venclexta for patients with AML and MDS.

A trial evaluating the tamibarotene-Vidaza combination in certain patients with newly diagnosed high-risk MDS will be discontinued.

I spent my life racing against time, until my cancer diagnosis forced me to hit the brakes.

Graft-versus-host disease prophylaxis using posttransplant cyclophosphamide remains a valid option for patients with myelodysplastic syndromes.

An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence for patients with MDS.

With my myelodysplastic syndrome and age, I find it hard to keep up; however, cancer and fatigue have taught me to live at my own pace.

While infections pose a risk for morbidity and mortality among patients with MDS, more needs to be studied about the topic, researchers urged.

An expert explained the burden that red blood cell transfusions can place on patients with MDS.

Having myelodysplastic syndromes has taught me to cherish every day and to pursue the things that matter to me, like publishing a book I’ve been writing.

Keri is also a true partner in the management and care of the whole patient.

Cancer has changed my self-image, but I’ve learned a few tricks to help boost my self-confidence.

Niktimvo was approved for adults and children with chronic, pretreated graft-versus-host disease.

Just like athletes in the Olympics, it's important for cancer survivors to keep track of everything they feel and to know their bodies well.

The National Comprehensive Cancer Network now recommends Rytelo for patients with myelodysplastic syndrome who require blood transfusions.

Post-transplant cyclophosphamide decreased the risk of complications in patients with blood cancers who underwent a stem cell transplant from an unrelated donor.

Although MDS didn’t leave physical scars, the invisible ones, like side effects from treatment, are ones that linger.

For patients with MDS who benefit from delaying transplants, it’s important to take care of their health while savoring their time before transplant.